No Data
No Data
Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Doing What It Can To Lift Shares
Hubei Biocause Pharmaceutical (000627.SZ): No share buyback transaction has been conducted.
On September 2, GeLongHui announced that as of August 31, 2024, Hubei Biocause Pharmaceutical (000627.SZ) has repurchased a total of 0 shares of the company through the special securities account for share repurchase, accounting for 0.00% of the total share capital of the company.
Tianmao Group: Guohua Life 2024 Semi-Annual Report
Tianmao Group: 2024 Semi-Annual Report
Tianmao Group: 2024 Semi-Annual Report Summary
Hubei Biocause Pharmaceutical (000627.SZ): Net loss of 0.365 billion yuan in the first half of the year, an expanded loss compared to the same period last year.
Hubei Biocause Pharmaceutical (000627.SZ) announced its semi-annual report for the year 2024, with a total operating income of 29.058 billion yuan, a year-on-year decrease of 13.08%; net income attributable to shareholders of listed companies -0.365 billion yuan, and an expanded loss compared to the same period last year; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses -0.369 billion yuan, and an expanded loss compared to the same period last year; basic earnings per share -0.074 yuan.
No Data
No Data